Proteasome Inhibitor Based Therapy for Treatment of Newly Diagnosed Multiple Myeloma

Multiple myeloma is a hematologic malignancy that is unable to be cured and has significant impact throughout the world. Front line treatment has shifted but ultimately has landed on a bortezomib based, combination therapy. Carfilzomib is a next generation proteasome inhibitor shown to improve both progression free survival and overall survival in relapsed and refractory multiple myeloma in combination with lenalidomide and dexamethasone (KRd). Given the favorable response rates seen in phase II trials treating newly diagnosed myeloma, this combination is listed as a viable option for upfront treatment.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Source Type: research